Inovio Pharmaceuticals Inc
INO
Get informed when a big investor buys or sells
+ FollowMarket Cap$61.98M
Close$
$0.74
17.6% downside
Current Fair Value
17.6% downsideOvervalued by 17.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $61.98 Million |
|---|---|
| Enterprise Value | $38.46 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.81 |
| Beta | 1.61 |
| Outstanding Shares | 81,619,113 |
Return
| Return on Equity | -1942959.72% |
|---|---|
| Return on Assets | -171956.37% |
| Return on Invested Capital | -916221.94% |
Valuation & Multiples
| P/E Ratio | -0.77 |
|---|---|
| PEG | 1.03 |
| Price to Sales | -0.9 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -588.56 |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 1.83 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
$533,333
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$2.27 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0493▼ 50.49% |
|---|---|
| Total Calls | 2,881,201▲ 571.47% |
| Total Puts | 142,100▼ 40.24% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 41.85%▼ 3.54% |
|---|---|
| Total Invested | $36.33M▼ 33.45% |
| Investors Holding | 112▲ 5.00% |
ESG Score
No data
About Inovio Pharmaceuticals Inc
112 employees
CEO: Jong Kim Inovio Pharmaceuticals, Inc. is a biotechnology firm focused on researching, developing, and bringing to market DNA-based treatments designed to address and safeguard individuals from conditions linked to human papillomavirus (HPV), vari...